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Abstract 28
Reduced lung function predicts mortality and is key to the diagnosis of COPD. In a genome-wide 29 association study in 400,102 individuals of European ancestry, we define 279 lung function signals, 30
one-half of which are new. In combination these variants strongly predict COPD in deeply-31 phenotyped patient populations. Furthermore, the combined effect of these variants showed 32 generalisability across smokers and never-smokers, and across ancestral groups. We highlight 33 biological pathways, known and potential drug targets for COPD and, in phenome-wide association 34 studies, autoimmune-related and other pleiotropic effects of lung function associated variants. This 35 new genetic evidence has potential to improve future preventive and therapeutic strategies for 36 COPD. 37 Introduction: 38 Impaired lung function is predictive of mortality 1 and is the key diagnostic criterion for chronic 39 obstructive pulmonary disease (COPD). Globally, COPD accounted for 2.9 million deaths in 2016 2 , 40 being one of the key causes of both Years of Life Lost and Years Lived with Disability worldwide 3 . 41
Determinants of maximally attained lung function and of lung function decline can influence the risk 42 of developing COPD. Tobacco smoking is the single largest risk factor for COPD, although other 43 environmental exposures and genetic makeup are important 4, 5 . Genetic variants associated with 44 lung function and COPD susceptibility can be causally informative, assisting with risk prediction, as 45 well as drug target identification and validation 6 . Whilst there has been considerable progress in 46
identifying genetic markers associated with lung function and risk of COPD 4,7-19 seeking a high yield 47
of associated genetic variants is key to progressing knowledge because: (i) implication of multiple 48 molecules in each pathway will be needed to build an accurate picture of the pathways 49 underpinning development of COPD; (ii) not all proteins identified will be druggable and; (iii) 50 combining information across multiple variants can improve prediction of disease susceptibility. 51
Through new detailed quality control and analyses of spirometric measures of lung function in UK 52
Biobank, completion of genome-wide genotyping in UK Biobank, and expansion of the SpiroMeta 53
Consortium, we undertook the largest genome-wide association study of lung function performed to 54 date. Comprising a total of 400,102 individuals of European ancestry, our study entailed a near 55 seven-fold increase in sample size over previous studies of similar ancestry to address the following 56 aims: (i) to generate a high yield of genetic markers associated with lung function; (ii) to confirm and 57 fine-map previously reported lung function signals; (iii) to investigate the putative causal genes and 58 biological pathways through which lung function associated variants act, and their wider pleiotropic 59 effects on other traits; and (iv) to generate a weighted genetic risk score for lung function and test 60
its association with COPD susceptibility in individuals of European and other ancestries. 61
Results:
62 139 new signals for lung function 63
Here we present a total of 279 distinct association signals for lung function, of which a half (139 64 variants) are new having reached genome-wide significance (P<5x10 -9 ) in this study. We increased 65 the sample size available for the study of quantitative measures of lung function in UK Biobank by 66 refining the quality control of spirometry based on recommendations of the UK Biobank Outcomes 67
Adjudication Working Group, utilising additional metrics derived from the blow curve time series 68 measurements, and relaxing the reproducibility threshold for repeat measures (Supplementary 69 Note). Genome-wide association analyses of forced expired volume in 1 second (FEV1), forced vital 70 capacity (FVC) and FEV1/FVC were then undertaken in 321,047 individuals in UK Biobank 71
( Supplementary Table 1 ) and in 79,055 individuals from the SpiroMeta Consortium (Supplementary  72  Tables 2 and 3) . A linear mixed model approach implemented in BOLT-LMM 20 was used for UK 73
Biobank to account for relatedness and fine-scale population structure (Online Methods). A total of 74 19,871,028 variants imputed in both UK Biobank and SpiroMeta were analysed. Peak expiratory flow 75
(PEF) was also analysed genome-wide in UK Biobank and up to 24,218 samples from SpiroMeta. All 76 individuals included in the genome-wide analyses were of European ancestry (Supplementary Figure  77 1 and Supplementary Table 2 ). 78
To maximise statistical power for discovery of new signals, whilst maintaining stringent significance 79 thresholds to minimise reporting of false positives, we adopted a study design incorporating both 80
two-stage and one-stage approaches (Figure 1) . In the two-stage analysis, 99 new distinct signals, 81 defined using conditional analyses, were associated with one or more traits at P<5x10 -9 in UK 82
Biobank and showed association (P<10 -3 ) with a consistent direction of effect in SpiroMeta ("Tier 1" 83 signals, Supplementary Figure 2; Supplementary Table 4 ). In the one-stage analysis, we meta-84
analysed UK Biobank and SpiroMeta (up to 400,102 individuals) and 40 additional new distinct 85 signals associated with one or more lung function traits reaching P<5x10 -9 were identified 86 ( Supplementary Figure 2, Supplementary Table 4 ) that were also associated with P<10 -3 separately 87
in UK Biobank and in SpiroMeta, with consistent direction of effect ("Tier 2" signals). An additional 88 323 signals were significantly associated with one or more lung function traits in the meta-analysis of 89 UK Biobank and SpiroMeta (P<5x10 -9 ) and reached P<10 3 for association in only one of UK Biobank 90
or SpiroMeta ("Tier 3" signals, Supplementary Table 5 ). Only the 139 signals meeting Tier 1 and Tier 91 2 criteria were followed up further. The strength and direction of association of the sentinel variant 92
(the variant in each signal with the lowest P value) for these 139 new signals across all 4 lung 93 function traits are shown in Figure 2 . 94
To assess whether any of these 139 signals associated with lung function could be driven via an 95
underlying association with smoking, we examined association of the sentinel variants with smoking 96 behaviour in UK Biobank (Online Methods). The only new sentinel associated with smoking 97 behaviour was rs193686 (in an intron of MET , Supplementary Table 6 ). Therefore, we tested for 98 association between this variant and lung function in never smokers (n=173,658). Whilst rs193686 99 was associated with smoking initiation (P=9.18x10 -6 ), the allele associated with smoking initiation 100 was associated with increased lung function in never smokers (FEV1/FVC P=5.28x10 -10 , 101 Supplementary Table 7) . Therefore, this signal was retained for further analysis. 102
A total of 279 signals of association for lung function 103
Of 157 previously published signals of association with lung function and COPD 3,6-18 , 142 were 104 associated at P<10 -5 in UK Biobank (Online Methods, Supplementary Figure 3 , Supplementary Table  105 8). Two sentinel variants (rs1689510 near RAB5B and rs11134789 in an intron of ADAM19) were 106 associated with smoking initiation (P=9.72x10 -6 and P=2.13x10 -5 , respectively) ( Supplementary Table  107 6), but were also associated with lung function in never smokers (P=2.49x10 -8 for FEV1 and 108 P=2.94x10 -45 for FEV1/FVC, respectively, Supplementary Table 7) . SNP rs17486278 at CHRNA5 and 109 rs11667314 near CYP2A6 were each associated with cigarettes per day (P=1.35x10 -79 and 110 P=6.47×10 -24 , respectively; Supplementary Table 6 ); neither were significantly associated with lung 111 function among never smokers, hence these latter two signals were excluded from further analysis. 112
This brings the total number of distinct signals of association with lung function to 279 113
( Supplementary Table 9 ). None of these variants showed interaction with ever-smoking status 114 (P>1.8x10 -4 , Online Methods, Supplementary Table 7 Methods). The latter were chosen based on previous reports of enrichment of lung function GWAS 147 signals in smooth muscle-containing tissues 18,33 . We identified 88 genes for which the most 148 significant SNP associated with expression of that gene in the respective eQTL resource was within 149 one of the 99% credible sets. These 88 genes were implicated by 58 of the 279 signals 150
( Supplementary Table 13 ). 151
We checked credible set variants for association with protein levels in a pQTL study 34 comprising SNP 152 associations for 3,600 plasma proteins. Using a Bonferroni-corrected 5% significance threshold for 153 276 tests for these 3,600 proteins (P < 5.03×10 -8 ), we found 1,076 pQTLs in our credible sets covering 154 26 lung function sentinels implicating 34 proteins. For 5 of these proteins the pQTL sentinel was 155 contained within our lung function credible set: ECM1, THBS4, NPNT, C1QTNF5 and SCARF2 156
( Supplementary Table 14 ). 157
In total, 107 putative causal genes were identified ( 
Pathway analysis 164
We tested whether these 107 putative causal genes were enriched in gene sets and biological 165 pathways (Online Methods), finding an enrichment of genes in elastic fibre and extracellular matrix 166 organisation pathways, and a number of gene ontologies including gene sets relating to the 167 cytoskeleton and processes involved in ciliogenesis (for example, cytoskeleton organisation, 168 organelle organisation, centriole replication and microtubule-based processes) ( Supplementary  169  Table 15 ). Whilst the enrichment in elastic fibre-related pathways is consistent with our previous 170 study 18 , enrichment in these pathways was further supported in this analysis by two new genes, 171
ITGAV (at a new signal) and GDF5 (a newly implicated gene for a previously reported signal), and by 172 strengthened eQTL evidence for TGFB2 and MFAP2 as the putative causal genes at two previously 173 reported signals. The presence of TGFB2, GDF5 and SMAD3 in our list of 107 genes resulted in 174 enrichment of a TGF-β superfamily signalling pathway (TGF-Core) and multiple related gene ontology 175 terms ( Supplementary Table 15 ). 176
Functional enrichment analyses 177
We tested for enrichment of the 279 Figure 4) . 182
We used DeepSEA 36 , a variant effect predictor which utilises a deep-learning algorithm, to identify 183 whether our signals were predicted to have a chromatin effect in lung-related cell lines. We 184 identified 10 signals (including 5 new signals) for which the SNP with the largest posterior probability 185 of being causal also had a significant predicted effect on a DNase I hypersensitivity site in lung-186 related cells ( Supplementary Table 16 ). This included a new signal near SMURF2 (17q24.1, 187 rs11653958) that also had a predicted functional effect on histone marks (DNase I hypersensitivity  188 sites, H3K9ac, H3K27ac, H3K4me1, H3K4me2, H3K4me3) and on CEBPB, FOSL2, SIN2AK-20 and 189
TCF12 transcription factor binding sites, and a new signal near PDZRN3-AS1 (rs586936) had a large 190 predicted effect on a CEBPB transcription factor binding site. 191
Drug targets 192
All 107 putative causal genes were interrogated against the gene-drug interactions table of the Gene Interactions Database (DGIDB) 37 (Supplementary our study, the allele associated with reduced expression of ITGAV ( Supplementary Table 13 ) was 201 associated with reduced risk of COPD ( Supplementary Table 9 ) suggesting that inhibitors of αvβ6 202 integrin might also have a beneficial effect in COPD. Another of our new signals is associated with 203 expression of TNFSF13 (synonym APRIL), a cytokine which is a member of the TNF ligand family. 204
Atacicept blocks B cell stimulation by TNFSF13 (as well as by BLyS) and reduced systemic lupus 205 erythematosus disease activity in a recent Phase IIb trial 40 . In our study, the allele associated with 206 decreased expression of TNFSF13 was associated with reduced FEV1, indicating that vigilance for 207 pulmonary consequences of atacicept may be warranted. 208
Genetic Risk Score: association with FEV1/FVC and COPD in multiple ancestries 209
We constructed a genetic risk score (GRS) weighted by FEV1/FVC effect sizes comprising all 279 new 210 or previously reported sentinel variants, and tested the association of the GRS with FEV1/FVC and 211 GOLD Stage 2-4 COPD (FEV1/FVC<0.7 and FEV1<80% predicted) in different ancestry groups in UK 212
Biobank, and China Kadoorie Biobank (Online Methods, Supplementary Table 18 ). The GRS was 213 associated with FEV1/FVC and COPD in each of the ancestry groups ( Figure 3A) . 214
We tested for a GRS interaction with smoking in European ancestry individuals in UK Biobank 41 . No 215 statistical interaction was seen for FEV1/FVC (interaction term -0.002 per SD change in GRS, 95% CI: 216
[0.009, 0.005], P=0.532), whilst the findings for COPD were consistent with a slightly smaller effect of 217 the GRS in ever-smokers (OR for ever-smoking-GRS interaction term per SD change in GRS 0.96, 95% 218 CI: [0.92, 0.99], P=0.015). 219
The association of the GRS with COPD susceptibility was additionally tested in deeply-phenotyped 220 case-control studies ( Supplementary Table 19 ). Similar effect size estimates were seen across each 221 of the 5 European ancestry studies ( Figure 3B) ; in the meta-analysis of these studies (n=6,979 cases 222 and 3,915 controls), the odds ratio for COPD per standard deviation of the weighted GRS was 1.55 223 (95% CI: [1.48, 1.62]), P=2.8710 -75 ( Supplementary Table 20 ). The GRS was also associated with 224 COPD in individuals of African-American ancestry in COPDGene (P=8.36x10 -7 ), albeit with a smaller 225 effect size estimate, odds ratio=1.26 (95% CI: [1.15, 1.37]). 226
To aid clinical interpretation, we divided individuals in each of the European ancestry deeply-227 phenotyped COPD case-control studies into deciles, according to their value of the weighted GRS. 228
The odds ratio for COPD in members of the highest GRS decile compared to the lowest GRS decile 229 was 4.73 (95% CI: [3.79, 5.90]), P=3.00x10 -43 (Figure 3C , Supplementary Table 21 ). We calculated the 230 population attributable risk fraction and estimated that the proportion of COPD cases attributable to 231 risk scores above the first GRS decile was 54.6% (95% CI: [50.6%, 58.4%]). 232
Pleiotropy and phenome-wide association studies 233
As phenome-wide association studies (PheWAS) can provide evidence mimicking pharmacological 234
interventions of drug targets in humans and informing drug development 42 , we undertook a PheWAS 235 of 2,411 phenotypes in UK Biobank (Online Methods, Figure 4) ; 226 of the 279 sentinel variants 236
were associated (FDR <1%) with one or more traits and diseases (excluding quantitative lung 237 function traits). Eighty-five of the lung function signals were associated with standing height. In 238 order to investigate whether the genetic association signals for lung function were driven by 239 incomplete adjustment for height, we tested for correlation of effects on lung function in UK 240
Biobank and height in the GIANT consortium for 247 of the 279 signals that had a proxy variant in 241 GIANT 43 ; there was no significant correlation (r=-0.096, Supplementary Figure 5) . Additionally, the 242
PheWAS revealed associations with body composition measures such as fat free mass (54 SNPs) and 243 hip circumference (40 SNPs), as well as muscle strength (32 SNPs, grip strength). One hundred and 244
fourteen of the 279 SNPs were associated with several quantitative measures of blood count, 245
including eosinophil counts and percentages (25 SNPs). Twenty-five of our SNPs were also associated 246 with asthma including 12 SNPs associated both with asthma and eosinophil measures. Five of these 247
SNPs were in LD (r 2 >0.1) with a SNP reported for association both with asthma and eosinophil 248 measures in previously published genome-wide association studies. To assess whether any of the 249 lung function associations could be driven by an association with asthma, we compared the effect 250 size estimated before and after exclusion of all self-reported asthma cases, observing remarkably 251 similar estimates (Supplementary Figure 6) suggesting that the lung function associations we report 252 are not primarily driven via known asthma signals. 253
We examined the specificity of genetic associations, given the potential for this to predict specificity 254 of drug target modification, and found that 53 of the 279 signals were associated only with lung 255 function and COPD-related traits. In contrast, three of our 279 signals were associated with over 100 256 traits across multiple categories -among these rs3844313, a known intergenic signal near HLA-DQB1 257 was associated with 163 traits, and also had the strongest signal in the PheWAS, which was for 258 association with intestinal malabsorption and coeliac disease. 259 260
In our 279-variant weighted GRS PheWAS analysis ( Supplementary Table 22 ), we found association 261 with respiratory traits including COPD, chronic bronchitis, emphysema, respiratory failure, 262 corticosteroid use and both paediatric and adult-onset asthma (Figure 5a) . The GRS was also 263 associated with non-respiratory traits including coeliac disease, an intestinal autoimmune disorder 264 (Figure 5b) . These pleiotropic effects on risk of autoimmune diseases was further confirmed by 265 analysis of previously reported GWAS (Online Methods, Supplementary Table 23 The unprecedented sample size of UK Biobank as a single cohort has revolutionised genetic studies. 318 We used two complementary study designs to maximise sample size for discovery and ensure 319 robustness of findings by requiring independent support for association. Furthermore, through 320 additional analysis of the spirometry data in UK Biobank and substantial expansion of the SpiroMeta 321 consortium, we have markedly increased samples sizes to almost seven times those included in 322 previous studies. As no lower MAF threshold was applied in our analyses, an overall threshold of 323
P<5x10 -9 , as recommended for re-sequencing analyses of European ancestry individuals 47 , was 324 applied. We identified the largest number of new signals in our more stringent two-stage design 325
("Tier 1", 99 new signals). Amongst the signals that we report as "Tier 3" (and did not include in 326
further analyses), all reached P<10 -3 in UK Biobank and 183 met a less stringent threshold of P<0.05 327
in SpiroMeta. 328
Our study is the first to investigate genome-wide associations with PEF. PEF is determined by various 329 physiological factors including lung volume, large airway calibre, elasticity of the lung and expiratory 330 muscle strength, is used for monitoring asthma, and was incorporated in a recently evaluated clinical 331 score for diagnosing COPD and predicting acute exacerbations of COPD 48 . Overall, 133 of the 279 332 signals were also associated with PEF (P<10 -5 ) and for 15 signals (including 4 new signals), PEF was 333 the most significantly associated trait. Of note, a signal near SLC26A9, a known cystic fibrosis 334 modifier gene 49 , was highly significantly associated with PEF in UK Biobank (P=3.97x10 -66 ) and was 335 nominally significant in SpiroMeta (P=6.93x10 -3 ), with consistent direction of effect, but did not meet 336 the Tier 2 criteria (P<10 -3 in each of SpiroMeta and UK Biobank). This could reflect the limited power 337
for PEF in SpiroMeta (up to 24,218 for PEF compared to 79,055 for the other three traits). 338
Examining associations of a given genetic variant with a wide range of human phenotypes is a 339 valuable tool in therapeutic target validation. As in our PheWAS, it can highlight variants which show 340 associations with one or more respiratory traits that might be expected to demonstrate greater 341 target specificity than variants associated with many traits. Additionally, in some instances, 342 association with multiple traits may indicate the relevance of drug repurposing. Association of a 343
given SNP with multiple traits does not necessarily imply shared aetiology, and further investigation 344 is warranted. Our GRS PheWAS assesses broader genetic overlap between lung function and other 345 traits and supports the evidence for some shared genetic determinants with autoimmune diseases. 346
In summary, our study has doubled the number of signals for lung function and, based on relating 347
fine-mapped, annotated variants to gene and protein expression, epigenetic marks, gene sets, 348
biological pathways and druggable proteins, it provides new understanding and resources of utility 349
for the development of therapeutics. The 279-variant GRS we constructed was associated with a 350 4.71-fold increased relative risk of moderate-severe COPD between highest and lowest deciles, such 351 that one would expect over 80% of smokers in the highest genetic risk decile to develop COPD. The 352
GRS was also predictive of COPD across multiple ancestral groups. Our PheWAS highlights both 353 expected and unexpected associations relevant to respiratory and other systemic diseases. 354
Investigating the nature of the pleiotropic effects of some of these variants will be of benefit for 355 drug target identification and validation. 356
Online Methods:
357
Study Design Overview and rationale 358
For the two-stage approach, we firstly selected distinct signals of association (defined using 359
conditional analyses) with one or more traits achieving P<5x10 -9 in UK Biobank only (n up to 360 321,047). A threshold of P<5x10 -9 was selected to maximise stringency of findings and to be 361 consistent with currently recommended genome-wide significance thresholds for re-sequencing 362 analyses of European ancestry individuals 50 . We then reported as new those signals which 363 additionally met P<10 -3 in SpiroMeta (N effective >70% of n up to 79,055; Supplementary Note, 364
Supplementary Figure 7) , with consistent directions of effect and term them "Tier 1" signals as they 365 meet our highest level of stringency. 366
For the one-stage approach, we selected distinct signals of association (defined using conditional 367 analyses) with one or more traits reaching P<5x10 -9 in the meta-analysis of UK Biobank and 368 SpiroMeta (n up to 400,102) and reported as new those which additionally met P<10 -3 in both UK 369
Biobank and SpiroMeta with a consistent direction of effect. We term these signals "Tier 2" as they 370 meet our second-highest level of stringency. 371
All signals meeting either set of criteria described above, and that had not been previously 372
published, were reported as new signals of association with lung function. Signals that reached 373
P<5x10 -9 in the meta-analysis of UK Biobank and SpiroMeta, had a consistent direction of effect in UK 374
Biobank and SpiroMeta, but which did not reach P<10 -3 in both UK Biobank and SpiroMeta are 375 presented as "Tier 3" and were not included in further analyses. 376
UK Biobank 377
The UK Biobank data resource is described elsewhere (see URLs). Individuals were selected for 378 inclusion in this study if they met the following criteria: (i) had complete data for age, sex, height and 379 smoking status; (ii) had spirometry meeting quality control requirements (based on analyses of 380 acceptability, reproducibility and blow curve metrics; Supplementary Note); (iii) had genome-wide 381 imputed genetic data and; (iv) were of European ancestry based on genetic data ( Supplementary  382 Note; Supplementary Figure 1) . Figure 8; Supplementary Table 24) . 396
SpiroMeta consortium 397
The SpiroMeta consortium meta-analysis was comprised of a total of 79,055 individuals from 22 398 studies. Thirteen studies (n=21,436 individuals) were imputed to the 1000 Genomes Project Phase 1 Supplementary Tables 2 and 3 for the  404 definitions of all abbreviations, study characteristics, details of genotyping platforms and imputation 405 panels and methods). Measurements of spirometry for each study are described in the 406 Supplementary Note. 407
In each study, linear regression models were fitted for each lung function trait (FEV 1 , FEV 1 /FVC, FVC 408 and PEF, where available), with adjustment for age, age 2 , sex and height. For studies with unrelated 409 individuals, these models were fitted separately in ever smokers and never smokers, with additional 410 adjustment for principal components of ancestry. Studies with related individuals fitted mixed 411 models in all individuals to account for relatedness, with ever smoking status as a covariate. 412
In all studies, rank-based inverse normal transformations were undertaken on the residuals, with 413 these transformed residuals used as the phenotype for association testing under an additive genetic 414 model ( Supplementary Table 3 ). 415
In the study level results, variants were excluded if they had a very low MAC ( Supplementary Table  416 3) or imputation quality (info) <0.3. In studies with unrelated individuals, the ever and never smokers 417 results were combined, using inverse variance weighted meta-analysis, to give an overall study 418 result. Genomic control was then applied to all study level results, before combining results across 419 all studies using inverse variance weighted meta-analysis. LD score regression intercepts for the 420 meta-analysis were close to 1 (Supplementary Figure 8 ; Supplementary Table 24 ) and so genomic 421 control was not applied. 422
Meta-analyses 423
A total of 19,871,028 variants (imputed or genotyped) in both UK Biobank and SpiroMeta were 424 meta-analysed using inverse-variance weighted fixed effect meta-analysis, and no further genomic 425 control was applied as LD score regression intercepts were close to 1 ( Supplementary Table 24 ). 426
Selection of new signals using conditional analyses 427
All SNPs ±1Mb were extracted around each sentinel variant. GCTA 55 was then used to perform 428 stepwise conditional analysis to select independently associated SNPs within each 2Mb region. Any 429 secondary signals identified within each 2Mb region were required to meet Tier 1 or Tier 2 criteria 430 (described above) after conditioning on the primary sentinel variant. A combined list of distinct lung 431 function signals was then made across the 4 phenotypes, FEV1, FVC, FEV1/FVC and PEF as follows: 432
where sentinel variants for 2 signals for different phenotypes were in high LD (r 2 > 0.5), we retained 433 the most significant variant; where 2 signals were in moderate LD (0.1 > r 2 > 0.5), we retained 434 variants if, after conditional analysis, they still met the Tier 1 or Tier 2 threshold; for signals in low LD 435 (r 2 < 0.1) we retained both variants. We then used the same criteria to identify a subset of new 436 signals which were distinct from previously published independent signals (see below). 437
Assessment of previously reported lung function signals 438
We identified 184 autosomal signals from previous GWAS analyses of lung function and COPD 1,4-14 . 439
After LD pruning (keeping only those signals with LD of r 2 < 0.1), we removed 24 non-independent 440
SNPs, leaving 160 previously reported independent signals. Of 6 previously reported signals in the 441 HLA region, we included only the 3 independent lung function HLA signals reported from conditional 442 analysis using all imputed HLA genotypes 18 : AGER (rs2070600), HLA-DQB1 (rs114544105) and near 443 ZNF184 (rs34864796) leaving 157 signals. 444
We confirmed association of previously reported signals in our data if they met any of three criteria: 445 (i) the previously reported sentinel was associated (P<10 -5 ) with any lung function trait in UK 446
Biobank; (ii) a proxy for the previously reported sentinel with r 2 >0.5 was associated (P<10 -5 ) with any 447 lung function trait in UK Biobank; (iii) a proxy for the previously reported sentinel with r 2 >0.1 was 448 associated with any lung function trait meeting tier 1 or tier 2 criteria (Supplementary Figure 3) . 449
Effect on COPD susceptibility -genetic risk score in multiple ancestries 450
To test association of all lung function signals and COPD susceptibility, we constructed a 279-variant 451 weighted GRS comprising the 139 novel and 140 previously reported signals; we used the previously 452 reported sentinel SNP for published signals. Weights were derived using the FEV1/FVC ratio 453 decreasing (i.e. COPD risk increasing) alleles. For previously reported signals (n=140), results from 454 the UK Biobank analysis were used to derive weights for the 94 signals that were not discovered 455 using UK Biobank data and weights were taken from SpiroMeta for 46 signals where UK Biobank was 456 included in the discovery of those signals. For novel signals identified in this study, weights were 457 taken from SpiroMeta for two-stage (tier 1) signals (n=99), and the smallest absolute effect size from 458 either of UK Biobank or SpiroMeta was used for one-stage (tier 2) signals (n=40) (Supplementary 459  Table 25 ). For the weighted GRS the number of risk alleles at each variant was multiplied by its 460
weight. 461
The GRS was first calculated in unrelated individuals (KING kinship coefficient of < 0.0884) within 6 462 ancestral groups of UK Biobank: Europeans, South Asians, Africans, Chinese, Mixed African and 463
Europeans, and Mixed Other (total sample of unrelated individuals across six ancestries: 323,001) 464 using PLINK. Weights and alleles were as described above. COPD was defined as FEV1/FVC < 0.7 and 465 FEV1 < 0.8 of the predicted value, i.e. GOLD stage 2-4 categorisation. Associations with the GRS were 466 then tested using COPD (in ancestral groups with at least 100 COPD cases) and FEV1/FVC as the 467 outcomes. 468
In addition, we calculated the GRS in individuals from the China Kadoorie Biobank (CKB). Four of the 469 279 SNPs were not available in CKB (rs1800888, rs56196860, rs72724130 and rs77672322), and for 470 12 SNPs, proxies were used (minimum r 2 =0.3). Analyses were undertaken in all COPD GOLD stage 2-4 471 cases (FEV1/FVC < 0.7 and FEV1 < 0.8 of the predicted value, in 6,013 cases and 69,567 controls), 472
against an unbiased set of population controls. The GRS was also tested for association with 473 FEV1/FVC in CKB (n=72, 796) . 474
Logistic regression of COPD case-control status with the GRS in UK Biobank and China Kadoorie 475
Biobank assumed an additive genetic effect and was adjusted for age, age 2 , sex, height, and smoking 476
( Supplementary Table 18 ). Ten principal components were also included in UK Biobank analyses. In 477
China Kadoorie Biobank, analyses were stratified by geographical regions and then meta-analysed 478
using an inverse-variance fixed effect model. Linear models assessing the association with FEV1/FVC 479 were fitted using the same transformed outcome as in the main GWAS analysis. 480
We then tested association in 5 European ancestry COPD case-control studies: COPDGene (Non-481 Hispanic White Population) (3,068 cases and 2,110 controls), ECLIPSE (1,713 cases and 147 controls), 482
GenKOLS (836 cases and 692 controls), NETT-NAS (374 cases and 429 controls) and SPIROMICS (988 483 cases and 537 controls) ( Supplementary Table 19 ). In addition, we tested this GRS in the COPDGene 484
African American population study (910 cases and 1,556 controls). Logistic regression models using 485 COPD as outcome and the GRS as exposure were adjusted for age, age 2 , sex, height, and principal 486 components ( Supplementary Table 20) . 487
Next, we divided individuals in the external COPD case-control studies into deciles according to their 488 values of the weighted GRS. This was undertaken separately by study group, and for each decile 489 logistic models were fitted, comparing the risk of COPD for members of each decile group compared 490 to those in the lowest decile (i.e. those with lowest values of the weighted GRS). Covariates were as 491 for the COPD analyses. Results were combined across European-ancestry study groups by fixed 492 effect meta-analysis (Supplementary Table 21) . 493
We calculated the population attributable risk fraction (PARF) as follows: 494
where P(E) is set to 0.9, i.e. the probability of carrying more risk alleles than those in the lowest risk 497 score decile of the risk score (the 'probability of the exposure'). OR refers to the odds of having 498 COPD in individuals across deciles 2 to 10 of the risk score compared to the odds of having COPD for 499 individuals in the lowest decile (decile 1) of the risk score (Supplementary Note) . 500
Effects on smoking behaviour 501
As our discovery GWAS in UK Biobank was adjusted for ever vs. never smoking status, and not for 502 pack years of smoking (pack years information was missing for 32% of smokers), we evaluated 503 whether any signals of association with lung function might be driven by an association with smoking 504 behaviour by testing for association with smoking initiation (123,890 ever smokers vs. 151,706 never 505 smokers) and cigarettes per day (n=80,015) in UK Biobank (full methods in Supplementary Note). 506 We also tested for association with lung function in never smokers only (n=173,658). We excluded 507 any signals associated with smoking behaviour (Supplementary Table 6 ), but not with lung function 508 in never smokers. 509
Smoking interaction 510
For associated variants (new and previously reported), we repeated association testing for lung 511 function separately in UK Biobank and SpiroMeta (up to 176,701 ever smokers and 197,999 never 512 smokers), and tested for an interaction effect with smoking using the Welch test (Supplementary 513 Note). A threshold of P<1.79x10 -4 (Bonferroni corrected for 279 tests) indicated significance. 514
We further tested for interaction between the weighted GRS and smoking, within 303,619 unrelated 515 individuals of European ancestry in UK Biobank, using COPD and FEV1/FVC as outcomes (the 516 FEV1/FVC phenotype was pre-adjusted for age, age 2 , sex, and height, and the residuals transformed 517
as per the main GWAS analysis). For COPD (defined as FEV1/FVC<0.7, and FEV1 <80% predicted) the 518 following logistic model was fitted: 519 COPD ~ genotyping array + 10 principal components + age + age 2 + sex + height + smoking status + 520 weighted risk score + (smoking status × weighted risk score). 521
For FEV1/FVC the following linear model was fitted: 522 FEV1/FVC ~ genotyping array + 10 principal components + smoking status + weighted risk score + 523
(smoking status x weighted risk score). 524
Proportion of variance explained 525
We calculated the proportion of variance explained by each of the previously reported (n=140) and 526 new variants (n=139) associated with lung function using the formula: 527
where n is the number of variants f i and β i are the frequency and effect estimate of the i'th variant, 529 and V is the phenotypic variance (always 1 as our phenotypes were inverse-normal transformed). 530
We used the same unbiased effect estimates (β) as used to calculate GRS weights at the same set of 531 279 sentinel variants used for the GRS, which uses either UK Biobank or SpiroMeta effect estimates 532 (described above). Our previously published estimate of proportion of variance explained 18 used 533 effect estimates derived from UK Biobank. We assumed a heritability of 40% 56,57 to estimate the 534 proportion of additive polygenic variance. 535
Fine-mapping 536
A Bayesian method 58 was used to fine-map lung-function-associated signals to the set of variants 537 that were 99% likely to contain the underlying causal variant (assuming that the causal variant has 538 been analysed). This was undertaken for new signals and for previously reported signals reaching 539 P<10 -5 in UK Biobank. For the previously reported signals, the top sentinel variant from the current 540 analysis in UK Biobank was used, instead of the previously reported variant. We used a value of 0.04 541 for the prior W in the approximate Bayes factor formula 59 . Effect sizes and standard errors for fine-542 mapping were obtained from an inverse variance weighted meta-analysis of UK Biobank and 543 SpiroMeta (n up to 400,102). Signals in the HLA region were not included. 544
Implication of potentially causal genes 545

Annotation of deleterious variants 546
Variants in the 99% credible sets were checked for predicted functional effect if they were 547 annotated as "exonic", "splicing", "ncRNA_exonic", "5' UTR" or "3' UTR" (untranslated region) by 548 ANNOVAR 60 . We then used SIFT, PolyPhen-2 (implemented using the Ensembl GRCh37 Variant 549
Effect Predictor, see URLs, accessed 1 February 2018) and FATHMM 61 to annotate missense variants, 550
and CADD (also implemented using VEP) to annotate non-coding variation. Variants were annotated 551
as deleterious in our study if they were labelled 'deleterious' by SIFT, 'probably damaging' or 552 'possibly damaging' by PolyPhen-2, 'damaging' by FATHMM (specifying the 'Inherited disease' option 553 of the coding variants methods, and setting the prediction algorithm to 'Unweighted') or had a CADD 554
scaled score ≥20 4 . The union of the four methods was taken to establish the number of potentially 555 deleterious variants and their unique genes. 556
Gene expression and protein levels 557
At each novel and previously reported signal, the sentinel variant and 99% credible set 58 were used 558 to query three eQTL resources: lung eQTL (n=1,111) 13 , blood eQTL (n=4,896) 62 and GTEx (V7; with n 559 up to 388 depending on tissue: Artery Aorta (n=267), Artery Coronary (n=152), Artery Tibial (n=388), 560
Colon Sigmoid (n=203), Colon Transverse (n=246), Esophagus Gastroesophageal Junction (n=213), 561
Esophagus Muscularis (n=335), Lung (n=383), Small Intestine Terminal Ileum (n=122), Stomach 562 (n=237), and Whole Blood (n=369)) 63 , and one blood pQTL resource (n=3,301) 34 . 563
A gene was classified as a 'putative causal gene' if the sentinel SNP or any SNP in the respective 99% 564 credible set was associated with expression of this gene or its protein levels (FDR<5% for eQTL, 565
P<5.03×10 -8 [for 276 tests at 3,600 proteins] for pQTL) and if the GWAS sentinel SNP or any SNP in 566 the respective 99% credible set was also the variant most strongly associated with expression of the 567 respective gene or level of the respective protein (i.e. the sentinel eQTL/pQTL SNP) in one or more of 568 the eQTL and pQTL data sets. The HLA region was excluded from these analyses. 569
Pathway analysis 570
We tested for enrichment of genes identified via variant function annotation, gene expression or 571 protein level analyses in pathway and gene set ontology databases using ConsensusPathdb. 572
Pathways or gene sets represented entirely by genes implicated by the same association signal were 573 excluded. Gene sets and pathways with FDR<5% are reported. 574
Functional enrichment analyses 575
We tested for cell-specific enrichment of lung function associated variants in regulatory regions 576 using FORGE 35 (v1.1). One thousand background SNP set repetitions were used. Thresholds 577 P<1.68x10 -4 (FDR<2%; >99 th percentile) and P<3.37 x 10 -5 (FDR<0.5%; >99.9 th percentile) were taken 578 as being 'indicative' and 'significant', respectively. FORGE analysis was carried out for the cell lines in 579
the RoadMap Epigenome project 33 (n=299 cell lines) and ENCODE projects 64 (n=125) separately. 580
Using DeepSEA 36 , we analysed all SNPs in the 99% credible set for predicted chromatin effects. We 581 reported effects for any chromatin effect and lung-related cell line that had an E-value<0.05 (i.e. the 582 expected proportion of SNPs with a larger predicted effect based on empirical distributions of 583 predicted effects for 1000 Genomes SNPs) and an absolute difference in probability of >0.1 584
(threshold for "high confidence") between the reference and alternative allele. 585
Drug targets 586
Genes identified as potentially causal using eQTL, pQTL or variant annotation were interrogated 587 against the gene-drug interactions MeSH headings) were added. 590
Phenome-wide association studies 591
To identify whether any of the new or previously reported signals overlap with signals of association 592
for other traits and diseases, the 279 variant weighted GRS was calculated in UK Biobank samples (n 593 up to 379,337) and a phenome-wide association study (PheWAS) across all available traits was 594 performed, with the risk score as the exposure. Traits included UK Biobank baseline measures (from 595 both questionnaires and physical measures), self-reported medication usage, and operative 596 procedures, as well as those captured in Office of Population Censuses and Surveys codes from the 597 electronic health record. We also included self-reported disease variables and those from hospital 598 episode statistics (ICD-10 codes truncated to three-character codes and combined in block and 599 chapter groups) as well as combining both self-report and hospital diagnosed diseases where 600 possible to maximise power. The GRS analysis included 2,453 traits, of which 2,411 were also 601 included in the single-variant analysis (traits with >200 cases were included for the individual SNP 602
PheWAS, whereas traits with >50 cases were included in the risk score PheWAS). Analyses were 603 conducted in unrelated European ancestry individuals (KING kinship coefficient of <0.0442), and 604
were adjusted for age, sex, genotyping array, and ten principal components. Logistic models were 605 fitted for binary outcome, and linear models were fitted for quantitative outcomes. False discovery 606 rates were calculated according to the number of the traits in each analysis (2,453 or 2,411, for the 607 risk score and single-variant PheWAS, respectively). 608
In addition, the sentinel variants and variants within the 99% credible sets were queried against the 609 GWAS catalog 65 (see URLs, accessed 5th February 2018) and GRASP 66 (see URLs, accessed 6th 610
February 2018) for reported associations significant at P<5x10 -8 . Associations relating to 611 methylation, expression, metabolite or protein levels, as well as lung function and COPD, were not 612 included. 613 Data availability statement 614 UK Biobank GWAS summary statistics will be available via UK Biobank 615 (http://www.ukbiobank.ac.uk/). SpiroMeta GWAS summary statistics, and single-variant PheWAS 616 results will be made available by request. 617 618
Figure 1: Study design 619
Tier 1 signals had P<5×10 -9 in UK Biobank and P<10 -3 in SpiroMeta with consistent direction of effect. 620
Tier 2 signals had P<5×10 -9 in the meta-analysis of UK Biobank and SpiroMeta with P<10 -3 in UK Biobank and P<10 -3 in 621
SpiroMeta with consistent directions of effect. Signals with P<5×10 -9 in the meta-analysis of UK Biobank and 622
SpiroMeta, and that had consistent directions of effect but did not meet P<10 -3 in both cohorts were reported as Tier Biobank (CKB). The left axis denotes odds ratios (OR) for COPD per 1 standard deviation (SD) increase in 633 weighted GRS (OR for COPD shown only for ancestries in UK Biobank with > 100 cases of COPD). COPD was 634 defined as FEV1/FVC < 0.7 and FEV1 < 0.8 of the predicted value, i.e. GOLD stage 2-4 categorisation. Bars (in 635 red) are labelled with ancestral groups, and the total sample size and number of COPD cases are given. The 636
right-hand axis denotes change in standard deviation (SD) units of FEV1/FVC per 1 SD increase in weighted 637 GRS in the same individuals (blue bars). For means and standard deviations of the risk scores in each group, 638
see Supplementary Table 18 five European-ancestry groups is denoted with a diamond, the width of which represents the 95% confidence interval for the estimate (I 2 statistic=0). 649
Figure 4: Individual PheWAS with 279 variants (traits passing FDR 1% threshold) 659
Separate association of 279 variants with 2,411 traits (FDR<1%) in UK Biobank (n up to 379,337). In each category, the trait with the strongest association, i.e. highest -660 log10(FDR), is shown first, followed by other traits in that category in descending order of -log10(FDR). Categories are colour-coded, and outcomes are denoted with a 661 circular or triangular point, according to whether they were coded as binary or quantitative. The top association per-category is labelled with its rsID number, and a plain 662
English label describing the trait. The letter at the beginning of each label allows easy cross-reference with the categories labelled in the legend. Zoomed in versions of each 663 category with visible trait names are available in Supplementary Figure 9 . 664 Association of 279 variant weighted genetic risk score with 2,453 traits (FDR<1%) in UK Biobank (n up to 379,337). In each panel, the category with the strongest 667 association, i.e. highest -log10(FDR), is shown first, followed by all other associations in that category, ordered by descending order of -log10(FDR). Sample sizes varied 668 across traits and are available in Supplementary Table 22 , along with the full summary statistics for each association, plus details of categorisation and plain English labels 669 for each trait. Trait categories are colour coded, and outcomes are denoted with a circular or triangular point, according to whether they were coded as binary or 670
quantitative. *QC refers to spirometry passing ERS/ATS criteria. 671
A. Associations with respiratory traits. 672 28 673
B. Associations with all other traits. 674 Supplementary Table 13 for direction of gene expression for the 678 COPD (lung function reducing) risk allele. 679
‡Genes implicated by pQTL signals: pQLT look up in 3,600 plasma proteins (n up to 3,300). 680 *Genes implicated because they contain a deleterious variant ( Supplementary Table 11 ).
681
"Other traits" column lists the other lung function traits for which the sentinel was associated at P<5×10 -9 in the meta-analysis of UK Biobank and SpiroMeta. 682 
